Anto Biosciences
Anto Biosciences is a YC Fall 2025 (F25) company. Based in San Francisco, CA, USA. Team of 2.
About Anto Biosciences
Summary
Anto Biosciences builds foundation models for microbial communities, making the gut microbiome computationally tractable for drug development. Its Darwin model series predicts how gut bacteria alter drug toxicity and efficacy across diverse patient populations, then optimizes molecules to improve outcomes. This replaces the current practice of treating microbiome variation as noise during drug development, addressing a root cause of clinical drug failures.
Go-to-market
Anto Biosciences targets pharmaceutical and biotech companies developing drugs where gut microbiome variation drives variable patient response, working with them to predict and fix failures before or during clinical development.
From the Y Combinator listing
A Foundation Model for Microbial Communities.
Anto is building a foundation model for microbial communities, making the gut microbiome computable for the first time. We predict drug toxicity and efficacy across diverse populations and fix drugs so they work for everyone — solving the hidden root cause of most drug failures. Founded by Arvid (Broad Institute of MIT and Harvard; Nature-published researcher who pioneered quality-aware, goal-directed sparsification) and David (Harvard Medical School Gastroenterology, J&J), second-time founders who published the breakthrough at leading machine learning AI conferences and Nature.
Facts
- Healthcare / Healthcare
- San Francisco, CA, USA
- 2
- Active
- Early
Founders (2)
- David Alexander de Gruijl
Score every batch against your own thesis
GPAgent's sourcing agent reads every company in a batch, scores each one against your fund's thesis in a private workspace, and lines up the founders worth meeting before Demo Day. You decide who to contact. Your scores, notes, and pipeline never appear on these pages.
How Accelerator intelligence works